TD Cowen raised the firm’s price target on Intercept to $19 from $11 and keeps a Market Perform rating on the shares. TD Cowen noted Intercept announced its acquisition by Alfasigma in a $19 per share cash deal with the transaction expected to close by year end 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ICPT:
- Intercept downgraded to Neutral from Buy at H.C. Wainwright
- Intercept downgraded to Hold from Buy at Canaccord
- Intercept downgraded to Neutral from Buy at B. Riley
- Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
- Alfasigma to acquire Intercept for $19.00 per share in cash
